FDA Approves Dupixent for Chronic Hives in Children Aged
Quick Facts
What Is Chronic Spontaneous Urticaria in Children?
Chronic spontaneous urticaria (CSU) is characterized by the sudden appearance of itchy wheals, angioedema, or both, persisting for more than six weeks without a clear external cause. In children, the condition can significantly disrupt sleep, school attendance, and emotional well-being, and is often associated with underlying immune dysregulation involving mast cell activation and IgE-mediated pathways.
Standard first-line treatment involves second-generation H1-antihistamines, sometimes at up to four times the standard dose. However, a substantial proportion of pediatric patients continue to experience symptoms despite this approach, leaving few well-studied options for younger children, who until now had no biologic therapy specifically approved for CSU.
How Does Dupixent Work for Hives?
Dupilumab is a fully human monoclonal antibody that inhibits signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), cytokines central to type 2 inflammation. By dampening this pathway, the drug reduces the inflammatory cascade that contributes to mast cell activation and chronic itch in conditions including atopic dermatitis, asthma, and eosinophilic esophagitis. The mechanism is distinct from antihistamines, which act on histamine receptors rather than upstream immune signaling.
The pediatric CSU approval was supported by clinical trials demonstrating that dupilumab reduced itch severity and hive activity in patients whose symptoms persisted despite antihistamine therapy. Dupixent is administered as a subcutaneous injection, with dosing adjusted by weight in younger children, and shares the well-characterized safety profile established across its other approved indications.
What Does This Approval Mean for Pediatric Care?
For families of children with refractory CSU, the expanded approval offers a targeted alternative to off-label immunosuppressants or escalating antihistamine regimens. Pediatric allergists and dermatologists now have an FDA-sanctioned biologic that addresses the underlying type 2 inflammation rather than only suppressing histamine response, potentially improving quality of life metrics including sleep and school performance.
Access considerations remain important, as biologic therapies typically require prior authorization and ongoing administration. Clinicians are expected to reserve dupilumab for children whose symptoms are inadequately controlled by guideline-recommended antihistamine therapy, in keeping with international urticaria treatment guidelines from the EAACI and the World Allergy Organization.
Frequently Asked Questions
Dupixent has an established safety profile in children as young as 6 months for atopic dermatitis. The most common side effects include injection site reactions and conjunctivitis. Parents should discuss individual risk factors with a pediatric specialist.
Dupixent is administered as a subcutaneous injection, with dosing based on the child's weight. After initial training, many caregivers can administer the injections at home according to a schedule set by the prescribing physician.
Treatment duration varies by patient. Some children achieve sustained remission and may taper under specialist guidance, while others require ongoing therapy. Decisions should be individualized based on response and disease activity.
References
- U.S. Food and Drug Administration. Dupixent (dupilumab) prescribing information and approval announcements.
- Sanofi and Regeneron Pharmaceuticals. Dupixent clinical development program communications.
- European Academy of Allergy and Clinical Immunology (EAACI) / World Allergy Organization (WAO). International guideline for the definition, classification, diagnosis and management of urticaria.
- Medical Xpress. FDA approves Dupixent for chronic spontaneous urticaria in young children. May 2026.